Sandbox reserved 1169
From Proteopedia
(Difference between revisions)
Line 9: | Line 9: | ||
== Structure == | == Structure == | ||
=== Overall Structure === | === Overall Structure === | ||
- | [[Image:Nuerotensin membrane.jpg |100 px|left|thumb| | + | [[Image:Nuerotensin membrane.jpg |100 px|left|thumb|Neurotensin Incorporation in Membrane ]] |
Like other G protein-coupled receptors, the neurotensin receptor is composed of 3 distinct regions. An extracellular binding site where neurotensin binds and causes a conformational change of the protein, a region containing <scene name='72/727765/Overall_structure/1'>7 transmembrane alpha helices</scene> that transduce the signal from the extracellular side of the cell membrane to the intracellular side, and an intracellular region that, when activated by a conformational change in the protein, activates a [https://en.wikipedia.org/wiki/G_protein G protein] associated with this receptor. There are currently no crystal structures of the inactive form of the neurotensin receptor available. Without a representation of the inactive form, the conformational changes caused by agonist binding are still not completely known. | Like other G protein-coupled receptors, the neurotensin receptor is composed of 3 distinct regions. An extracellular binding site where neurotensin binds and causes a conformational change of the protein, a region containing <scene name='72/727765/Overall_structure/1'>7 transmembrane alpha helices</scene> that transduce the signal from the extracellular side of the cell membrane to the intracellular side, and an intracellular region that, when activated by a conformational change in the protein, activates a [https://en.wikipedia.org/wiki/G_protein G protein] associated with this receptor. There are currently no crystal structures of the inactive form of the neurotensin receptor available. Without a representation of the inactive form, the conformational changes caused by agonist binding are still not completely known. | ||
=== Neurotensin Binding Site === | === Neurotensin Binding Site === |
Revision as of 21:04, 29 March 2016
Neurotensin Receptor (Rattus norvegicus)
|
References
- ↑ Millar RP, Newton CL. The year in G protein-coupled receptor research. Mol Endocrinol. 2010 Jan;24(1):261-74. Epub 2009 Dec 17. PMID:20019124 doi:10.1210/me.2009-0473
- ↑ Gui X, Carraway RE. Enhancement of jejunal absorption of conjugated bile acid by neurotensin in rats. Gastroenterology. 2001 Jan;120(1):151-60. PMID:11208724
- ↑ Selivonenko VG. [The interrelationship between electrolytes and phase analysis of systole in toxic goiter]. Probl Endokrinol (Mosk). 1975 Jan-Feb;21(1):19-23. PMID:1173461
- ↑ Fang Y, Lahiri J, Picard L. G protein-coupled receptor microarrays for drug discovery. Drug Discov Today. 2004 Dec 15;9(24 Suppl):S61-7. PMID:23573662
- ↑ 5.0 5.1 White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012 Oct 25;490(7421):508-13. doi: 10.1038/nature11558. Epub 2012 Oct 10. PMID:23051748 doi:http://dx.doi.org/10.1038/nature11558
- ↑ Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999 Jul;20(7):302-9. PMID:10390649
- ↑ 7.0 7.1 7.2 White JF, Noinaj N, Shibata Y, Love J, Kloss B, Xu F, Gvozdenovic-Jeremic J, Shah P, Shiloach J, Tate CG, Grisshammer R. Structure of the agonist-bound neurotensin receptor. Nature. 2012 Oct 25;490(7421):508-13. doi: 10.1038/nature11558. Epub 2012 Oct 10. PMID:23051748 doi:http://dx.doi.org/10.1038/nature11558
- ↑ Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, Stevens RC. Allosteric sodium in class A GPCR signaling. Trends Biochem Sci. 2014 May;39(5):233-44. doi: 10.1016/j.tibs.2014.03.002. Epub , 2014 Apr 21. PMID:24767681 doi:http://dx.doi.org/10.1016/j.tibs.2014.03.002
- ↑ Valerie NC, Casarez EV, Dasilva JO, Dunlap-Brown ME, Parsons SJ, Amorino GP, Dziegielewski J. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Cancer Res. 2011 Nov 1;71(21):6817-26. doi: 10.1158/0008-5472.CAN-11-1646. Epub, 2011 Sep 8. PMID:21903767 doi:http://dx.doi.org/10.1158/0008-5472.CAN-11-1646
- ↑ Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009 Aug 15;69(16):6539-45. doi: 10.1158/0008-5472.CAN-09-0418. PMID:19679549 doi:http://dx.doi.org/10.1158/0008-5472.CAN-09-0418